Novel activities of safe-in-human broad-spectrum antiviral agents

Aleksandr Ianevski; Eva Zusinaite; Suvi Kuivanen; Mårten Strand; Hilde Lysvand; Mona Teppor; Laura Kakkola; Henrik Paavilainen; Mira Laajala; Hannimari Kallio-Kokko; Miia Valkonen; Anu Kantele; Kaidi Telling; Irja Lutsar; Pille Letjuka; Natalja Metelitsa; Valentyn Oksenych; Magnar Bjørås; Svein Arne Nordbø; Uga Dumpis; Astra Vitkauskiene; Christina Öhrmalm; Kåre Bondeson; Anders Bergqvist; Tero Aittokallio; Rebecca J. Cox; Magnus Evander; Veijo Hukkanen; Varpu Marjomaki; Ilkka Julkunen; Olli Vapalahti; Tanel Tenson; Andres Merits; Denis Kainov

doi:10.1016/j.antiviral.2018.04.016

Novel activities of safe-in-human broad-spectrum antiviral agents

Aleksandr Ianevski
, Eva Zusinaite
, Suvi Kuivanen
, Mårten Strand
, Hilde Lysvand
, Mona Teppor
, Laura Kakkola
, Henrik Paavilainen
, Mira Laajala
, Hannimari Kallio-Kokko
, Miia Valkonen
, Anu Kantele
, Kaidi Telling
, Irja Lutsar
, Pille Letjuka
, Natalja Metelitsa
, Valentyn Oksenych
, Magnar Bjørås
, Svein Arne Nordbø
, Uga Dumpis

Astra Vitkauskiene, Christina Öhrmalm, Kåre Bondeson, Anders Bergqvist, Tero Aittokallio, Rebecca J. Cox, Magnus Evander, Veijo Hukkanen, Varpu Marjomaki, Ilkka Julkunen, Olli Vapalahti, Tanel Tenson, Andres Merits, Denis Kainov^*

^*Corresponding author for this work

Department of Clinical and Molecular Medicine
Norwegian University of Science and Technology
Institute of Technology
University of Tartu
Department of Virology
University of Helsinki
Department of Clinical Microbiology
Umeå University
Institute of Biomedicine
University of Turku
Department of Biological and Environmental Science
University of Jyväskylä
Department of Virology and Immunology
Helsinki University Central Hospital
Institute of Medical Microbiology
Narva
St. Olavs Hospital
Department of Medical Microbiology
Paula Stradina Clinical University Hospital
Department of Laboratory Medicine
Lithuanian University of Health Sciences
Department of Medical Sciences
Uppsala University
Institute for Molecular Medicine Finland
Department of Mathematics and Statistics
Department of Clinical Science
University of Bergen
Department of Veterinary Biosciences

Research output: Contribution to journal › Article › peer-review

67 Citations (Scopus)

Abstract

According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.

Original language	English
Pages (from-to)	174-182
Number of pages	9
Journal	Antiviral Research
Volume	154
DOIs	https://doi.org/10.1016/j.antiviral.2018.04.016
Publication status	Published - Jun 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.antiviral.2018.04.016

Cite this

Ianevski, A., Zusinaite, E., Kuivanen, S., Strand, M., Lysvand, H., Teppor, M., Kakkola, L., Paavilainen, H., Laajala, M., Kallio-Kokko, H., Valkonen, M., Kantele, A., Telling, K., Lutsar, I., Letjuka, P., Metelitsa, N., Oksenych, V., Bjørås, M., Nordbø, S. A., ... Kainov, D. (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research, 154, 174-182. https://doi.org/10.1016/j.antiviral.2018.04.016

@article{f939e4c14f384025b6cbfc35d08f98cc,

title = "Novel activities of safe-in-human broad-spectrum antiviral agents",

abstract = "According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.",

author = "Aleksandr Ianevski and Eva Zusinaite and Suvi Kuivanen and M{\aa}rten Strand and Hilde Lysvand and Mona Teppor and Laura Kakkola and Henrik Paavilainen and Mira Laajala and Hannimari Kallio-Kokko and Miia Valkonen and Anu Kantele and Kaidi Telling and Irja Lutsar and Pille Letjuka and Natalja Metelitsa and Valentyn Oksenych and Magnar Bj{\o}r{\aa}s and Nordb{\o}, \{Svein Arne\} and Uga Dumpis and Astra Vitkauskiene and Christina {\"O}hrmalm and K{\aa}re Bondeson and Anders Bergqvist and Tero Aittokallio and Cox, \{Rebecca J.\} and Magnus Evander and Veijo Hukkanen and Varpu Marjomaki and Ilkka Julkunen and Olli Vapalahti and Tanel Tenson and Andres Merits and Denis Kainov",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier B.V.",

year = "2018",

month = jun,

doi = "10.1016/j.antiviral.2018.04.016",

language = "English",

volume = "154",

pages = "174--182",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier B.V.",

}

Ianevski, A, Zusinaite, E, Kuivanen, S, Strand, M, Lysvand, H, Teppor, M, Kakkola, L, Paavilainen, H, Laajala, M, Kallio-Kokko, H, Valkonen, M, Kantele, A, Telling, K, Lutsar, I, Letjuka, P, Metelitsa, N, Oksenych, V, Bjørås, M, Nordbø, SA, Dumpis, U, Vitkauskiene, A, Öhrmalm, C, Bondeson, K, Bergqvist, A, Aittokallio, T, Cox, RJ, Evander, M, Hukkanen, V, Marjomaki, V, Julkunen, I, Vapalahti, O, Tenson, T, Merits, A & Kainov, D 2018, 'Novel activities of safe-in-human broad-spectrum antiviral agents', Antiviral Research, vol. 154, pp. 174-182. https://doi.org/10.1016/j.antiviral.2018.04.016

TY - JOUR

T1 - Novel activities of safe-in-human broad-spectrum antiviral agents

AU - Ianevski, Aleksandr

AU - Zusinaite, Eva

AU - Kuivanen, Suvi

AU - Strand, Mårten

AU - Lysvand, Hilde

AU - Teppor, Mona

AU - Kakkola, Laura

AU - Paavilainen, Henrik

AU - Laajala, Mira

AU - Kallio-Kokko, Hannimari

AU - Valkonen, Miia

AU - Kantele, Anu

AU - Telling, Kaidi

AU - Lutsar, Irja

AU - Letjuka, Pille

AU - Metelitsa, Natalja

AU - Oksenych, Valentyn

AU - Bjørås, Magnar

AU - Nordbø, Svein Arne

AU - Dumpis, Uga

AU - Vitkauskiene, Astra

AU - Öhrmalm, Christina

AU - Bondeson, Kåre

AU - Bergqvist, Anders

AU - Aittokallio, Tero

AU - Cox, Rebecca J.

AU - Evander, Magnus

AU - Hukkanen, Veijo

AU - Marjomaki, Varpu

AU - Julkunen, Ilkka

AU - Vapalahti, Olli

AU - Tenson, Tanel

AU - Merits, Andres

AU - Kainov, Denis

PY - 2018/6

Y1 - 2018/6

N2 - According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.

AB - According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.

UR - https://www.scopus.com/pages/publications/85046170096

U2 - 10.1016/j.antiviral.2018.04.016

DO - 10.1016/j.antiviral.2018.04.016

M3 - Article

C2 - 29698664

AN - SCOPUS:85046170096

SN - 0166-3542

VL - 154

SP - 174

EP - 182

JO - Antiviral Research

JF - Antiviral Research

ER -

Novel activities of safe-in-human broad-spectrum antiviral agents

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this